#USA #Bioinformatics #Bozeman #Golden Helix #Genomenon

Golden Helix and Genomenon Join Forces for Advanced Clinical Diagnostics

In a major development in the field of clinical genomics, Golden Helix, a global pioneer in clinical bioinformatics, has announced a strategic partnership with Genomenon. This collaboration focuses on integrating Genomenon's Mastermind Genomic Intelligence Platform and Cancer Knowledgebase (CKB) into Golden Helix's software suite, which is expected to significantly enhance the capabilities of genomic interpretation in clinical laboratories worldwide.

Enhancing Genomic Interpretation

The integration of these two industry-leading platforms brings together a wealth of resources aimed at delivering high-confidence, literature-backed insights. Golden Helix's customers will benefit from seamless access to Genomenon's curation of germline and somatic content directly within VarSeq's annotation engine, establishing a more efficient workflow for both inherited diseases and cancers. This integration combines expertly curated data with other trusted public resources, such as ClinVar, providing a comprehensive solution for variant interpretation.

Mike Klein, CEO of Genomenon, expressed pride in collaborating with Golden Helix, highlighting the benefits of their partnership: “This integration empowers labs to make faster, more confident clinical decisions by surfacing the most relevant scientific literature and curated genetic data exactly where and when it's needed.”

Streamlined Workflow for Clinical Labs

With the integration, Golden Helix customers can now streamline variant interpretation processes. This revolutionary approach allows clinical laboratories to prioritize variant interpretations significantly more efficiently, thus improving patient outcomes. By leveraging Genomenon’s detailed literature and pathogenicity insights within Golden Helix's trusted framework, labs can reduce manual curation times, accelerate turnaround, and produce evidence-backed reports that are more consistent and accurate.

Dr. Andreas Scherer, President and CEO of Golden Helix, noted the positive implications of this partnership, stating, “This partnership allows us to deliver deeply curated literature, pathogenicity insights, and oncology knowledge within the trusted Golden Helix framework our customers rely on every day.”

Key Benefits of the Collaboration

The key advantages of this collaboration include:

• - Enhanced Access: Customers will have direct access to curated genomic content for both inherited diseases and cancers seamlessly integrated into their workflows.
• - High-Confidence Insights: The combined information delivers insights into variant pathogenicity, biomarker associations, therapeutic relevance, and diagnostic criteria.
• - Time Efficiency: Labs can significantly diminish the time spent on manual curation, enabling a quicker process to producing actionable insights.
• - Flexibility: The integration is designed to be implemented on-premises, in the cloud, or within hybrid infrastructures, ensuring data control and regulatory compliance.

As the demand for precision medicine grows, Golden Helix continues to evolve its offerings, helping diagnostic labs worldwide to meet these shifting needs effectively.

For those interested, demos are available, and further information can be accessed on Golden Helix's website.

About the Companies

Genomenon

Genomenon is a genomic intelligence company dedicated to improving patient care through the understanding of genomic drivers behind genetic diseases and cancers. Utilizing AI and a comprehensive genomic dataset, Genomenon transforms complex genetic data into actionable insights.

Golden Helix

With over 25 years of experience, Golden Helix has provided trusted bioinformatics solutions to a variety of clients, including hospitals and testing labs. Their powerful tools facilitate the discovery of disease-causing mutations, personalization of treatment choices, and advancements in research for rare diseases and oncology.

This partnership marks a significant step in modernizing clinical diagnostics, ultimately propelling the field of genomics into a new age of efficacy and precision.